Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis - European Medical Journal

This site is intended for healthcare professionals

Continue

Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis

Dermatology

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.